RYESX | VENAX | RYESX / VENAX | |
Total Expense Ratio | 1.65 | 0.09 | 1,833% |
Annual Report Gross Expense Ratio | 1.68 | 0.09 | 1,867% |
Fund Existence | 21 years | 21 years | - |
Gain YTD | -11.731 | 0.937 | -1,251% |
Front Load | 5% | N/A | - |
Min. Initial Investment | 2500 | 100000 | 3% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 5.01M | 8.68B | 0% |
Annual Yield % from dividends | 0.00 | 3.27 | - |
Returns for 1 year | -26.61 | -5.38 | 495% |
Returns for 3 years | 0.25 | 11.43 | 2% |
Returns for 5 years | 73.43 | 143.68 | 51% |
Returns for 10 years | -61.24 | 25.58 | -239% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
TSMG | 18.31 | 0.04 | +0.21% |
Leverage Shares 2X Long Tsm Daily ETF | |||
GMAY | 39.64 | 0.03 | +0.08% |
FT Vest U.S. Eq Mod Buffr ETF - May | |||
SBIO | 33.12 | 0.01 | +0.02% |
ALPS Medical Breakthroughs ETF | |||
CORP | 96.69 | -0.12 | -0.12% |
PIMCO Investment Grade Corporate Bd ETF | |||
BNDD | 12.19 | -0.09 | -0.74% |
Quadratic Deflation ETF |